Parameter
| Biomarker | mEVs | Full name | Medium Extracellular Vesicles | Molecular Type | Protein/Nucleic acid/Lipid |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis |
| Disease | PCa | Disease Subtypes | / | ||
| Organ | Prostate | Test Sample / Technology Platform | Plasma, urine (flow cytometry, ELISA) | ||
| Pathobiological Mechanisms | The delivered miR-153, miR-424, and other miRNAs can regulate downstream target genes, promoting tumor cell proliferation and invasion. Surface proteins (e.g., CD151) are positively correlated with the metastatic potential and poor prognosis of tumors. | ||||
| Clinical Availability Status | Clinical research/early clinical validation | ||||
| Notes and Dynamics | As targeted drug delivery vehicles, mEVs are used to enhance the efficacy of chemotherapy drugs while reducing side effects. The future trend is to integrate proteomic, miRNAomic, and lipidomic data from mEVs, rather than relying on a single biomarker. | ||||